{
  "drug_name": "Flucloxacillin",
  "tradename": "Floxapen, Lutropin, Staphcil",
  "usage_and_dosing": {
    "general_info": [
      "An oral penicillinase-resistant antistaphylococcal antibiotic with activity similar to Dicloxacillin.",
      "Not active vs. methicillin-resistant Staphylococcus aureus (MRSA).",
      "Relatively poor activity vs. Strep. pyogenes; Penicillin G (IV) or Penicillin V (po) is preferred.",
      "For oral use for MSSA, Flucloxacillin is interchangeable with Dicloxacillin.",
      "Due to risk of cholestatic hepatitis, use only for severe infections. See Adverse Effects.",
      "Allergy: Protocol for Flucloxacillin desensitization."
    ],
    "adult_dose": [
      "Oral: 250-500 mg po q6h",
      "Parenteral: 1-2 gm IV q4-6h"
    ],
    "pediatric_dose": [
      {
        "age": "<2 yrs",
        "dose": "62.5-125 mg po q6h or 25 mg/kg IV q4-6h"
      },
      {
        "age": "2-10 yrs",
        "dose": "125-250 mg po q6h or 25-50 mg/kg IV q6h"
      }
    ],
    "renal_adjustment": {
      "half_life_hrs_renal_function_normal": 0.75,
      "half_life_hrs_esrd": "No data",
      "dose_renal_function_normal": [
        "250-500 mg po q6h",
        "1-2 gm IV q4-6h"
      ],
      "crcl_or_egfr": "Dosage recommendations not available. Consider 50% reduction if CrCl <10 mL/min",
      "hemodialysis": "No data (not significantly removed by HD)",
      "capd": "No data",
      "crrt": "CVVH: 4 gm IV q8h",
      "sled": "1 gm IV q4h"
    },
    "hepatic_adjustment": "No data"
  },
  "adverse_effects": [
    "GI (nausea, vomiting, diarrhea, C. difficile infection)",
    "Hypersensitivity",
    "Cholestatic hepatitis:",
    "Incidence estimated at 1 in 15,000 exposures.",
    "Occurs more frequently in patients >55 years of age, in females, and in patients treated for >2 weeks.",
    "Cholestasis can appear up to several weeks after the end of therapy and can take weeks to resolve.",
    "Drug-induced liver injury (DILI) related to flucloxacillin is associated with HLA-B*57:01 in a genome-wide association study (Nat Genet 2009;41:816).",
    "DILI is selective for flucloxacillin on the basis of HLA restriction, and no cross-reactivity with other beta-lactams is apparent. Given the low positive predictive value of this allele for DILI, testing is not a part of routine clinical practice (N Engl J Med 2019;381:2338).",
    "Hematologic: leukopenia, anemia, thrombocytopenia."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "use_during_lactation": "Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity."
  },
  "antimicrobial_spectrum": {
    "preferred": [
      "Staphylococcus aureus, methicillin-sensitive (MSSA)",
      "Staphylococcus epidermidis, methicillin-susceptible (MSSE)",
      "Staphylococcus lugdunensis",
      "Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"
    ],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "pharmaceutical_preparations": [
      "Cap (250, 500 mg)",
      "Oral syrup (125 mg/5 mL, 250 mg/5 mL)",
      "Injection"
    ],
    "food_rec_po_drugs": "Cap no food",
    "oral_absorption_percent": 50,
    "tmax_hr": "po: 1",
    "peak_serum_conc_mcg_ml": "10 (250 mg po, SD)",
    "protein_binding_percent": 95,
    "avg_serum_t1_2_hr": 0.75,
    "elimination": "Renal"
  },
  "enzyme_transporter_mediated_interactions": {
    "cyp450s_induced_by_drug": "CYP3A4?",
    "transporters_induced_by_drug": "PGP?",
    "impact_on_serum_drug_concentrations": "↓"
  },
  "major_drug_interactions": [
    {
      "drug": "Isavuconazonium",
      "effect_on_conc": "↓ isavuconazole",
      "management": "Monitor, adjust (EJCMID 2022)"
    },
    {
      "drug": "Posaconazole",
      "effect_on_conc": "↓ posaconazole",
      "management": "Monitor, adjust (JAC 2023 Apr 1)"
    },
    {
      "drug": "Probenecid",
      "effect_on_conc": "↑ flucloxacillin",
      "management": "Monitor, adjust"
    },
    {
      "drug": "Tacrolimus",
      "effect_on_conc": "↓ tacrolimus",
      "management": "Monitor, adjust (Eur J Clin Pharmacol)"
    },
    {
      "drug": "Voriconazole",
      "effect_on_conc": "↓ voriconazole",
      "management": "Monitor, adjust (AAC 61:e0091)"
    },
    {
      "drug": "Warfarin",
      "effect_on_conc": "↓ warfarin",
      "management": "Monitor INR, adjust (Int Med J 48:8)"
    }
  ]
}